G1 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

G1 Therapeutics

03/05/2023 14:32

* G1 Therapeutics Inc  GTHX.OQ  reported a quarterly
adjusted loss
of 53 cents​​ per share for the quarter ended in March. The mean
expectation of eight analysts for the quarter was for a loss
of 64 cents per share.
    * Revenue rose 87.6% to $12.95 million from a year ago;
analysts
expected $11.19 million. 
    * G1 Therapeutics Inc's reported EPS for the quarter was a
loss
of 53 cents​.
    * The mean earnings estimate of analysts had risen by
about 20.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * G1 Therapeutics Inc shares had risen by 10.8% this
quarter and
lost 45.3% so far this year.
    * The company reported a quarterly loss of $27.6 million.
    * Wall Street's median 12-month price target for G1
Therapeutics
Inc is $14.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
3 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.64          -0.53          Beat
 Dec. 31 2022      -0.84          -0.73          Beat
 Sep. 30 2022      -0.63          -0.59          Beat
 Jun. 30 2022      -1.02          -0.92          Beat